Monday, 30 July 2018

BioLargo Spotlight Blog Post: Clyra Medical Technologies Hires New Director of Product Development


BioLargo is pleased to welcome a new member to our team, Julian Bejarano, PhD, who will hold the position of Director of Product Development at Clyra Medical Technologies. Julian will work closely with our leadership group to help create and refine new medical products under the umbrella of our Clyra advanced wound care product line. As Director of Product Development for Clyra, Julian will be responsible for bringing health care products to market from concept to commercialization. He will use the patented antimicrobial technology owned by Clyra to develop new products and formulas for dental applications, skin care, wound healing, skin regeneration, and bone replacement procedures, as well as other relevant products related to the healthcare field. Dr. Bejarano will evaluate nanoencapsulation approaches to boost the efficacy of active agents and improve the biocompatibility and physical features of the final product. He will also lead the planning, design and execution of studies to provide proof of concept, safety, and efficacy depending on the regulatory pathway of product development. We are very excited about the value he will add to Clyra and the entire company. 













Julian is an expert scientific researcher with more than 11 years of experience leading fundamental and applied research projects related to materials science and nanotechnology. In particular, he has six years of experience in projects related to biomaterials for regenerative medicine and multifunctional nanoparticles for controlled drug delivery. Julian holds a Materials Engineering degree and a Masters in Materials Engineering from the Universidad del Valle, Colombia. He also holds a PhD in Engineering Sciences with emphasis in Materials Science from the Universidad de Chile, Chile. Julian was a visiting researcher during his PhD studies at the Institute of Biomaterials at the University of Erlangen-Nuremberg, Germany. Following his doctorate studies, Dr. Bejarano was a postdoctoral fellow at the Advanced Center for Chronic Diseases in Chile for three years and Research Advisor for the Group of Polymer Engineering at the Universidad de Chile. Moreover, he has outstanding skills in project management, R&D, and innovation. His projects have been focused on the development and characterization of composites materials based on metals, polymers and ceramics, synthesis of multifunctional nanoparticles, encapsulation of therapeutic agents, and biological evaluation of materials. His findings in materials research have been published by prestigious international journals and he has presented at several international events related to biomaterials and materials science.

Steve Harrison, President of Clyra Medical Technologies commented, “Julian brings unique and highly specialized knowledge and talent to the company. He will play an important role in helping us expand our product portfolio as we gear up for our commercial launch.” 








What is a BioLargo Spotlight?
It’s an exciting time at BioLargo. We’re moving fast, and it can be difficult to keep our stockholders and the investing public informed of our progress. In light of this, we will be posting a series of short articles titled “BioLargo Spotlight”, highlighting certain business activities and other important information in between our required SEC filings. Of course, these do not replace our public filings, which contain more complete information than can be delivered in this forum, and thus we urge you to carefully read and rely on those filings for definitive information, and to review our risk factors and caution regarding forward-looking statements. We are optimistic about our business as we work hard to continue to grow and ultimately generate profits for our stockholders.   

Legal Disclaimer
Our attorneys remind us that while we believe these developments are important and that these small victories could add up and lead to big victories, at this stage they do not rise to the level of an official material disclosure. As the size and magnitude of these developments become material, we will naturally report that information in an 8-K and our regular SEC filings.


Thursday, 26 July 2018

Uptick Interview with Dennis Calvert: BioLargo Enjoying Commercial Successes and Set to Begin Pilots for AOS


BioLargo President and CEO Dennis Calvert appeared July 24,2018 on Uptick Newswire’s Stock Day Podcast with Everett Jolly to discuss recent news at BioLargo. Recent months have seen many important milestones being checked off by the company, and the coming months will see several highly significant milestones including pilot projects for the company’s disruptive technologies.


Dennis discussed CupriDyne Clean commercial successes, ClyraMedical Technologies, and upcoming AOS pilots:

CupriDyne Clean:
  • CupriDyne Clean recognized as the number one product on the market for industrial odor and VOC control
  • Offered at value pricing – 25% to 50% cost savings
  • Currently working with all the major waste handling companies and expanding through regional adoption
  • Now offering turn-key design/build/install/maintain odor-control delivery systems
  • Team is highly respected and trusted as experts in odor control; unparalleled service team

Clyra:
  • Recent FDA 510(k) application in process
  • Advanced wound care market is an $18B global segment
  • Silver, the leading microbial used in advanced wound care, is coming under regulatory pressure in the EU
  • Strategic relationships in development

AOS Pilots:
  • Management confident of AOS scale-up capabilities
  • Pilots organizing to prove OPEX and CAPEX in the field
  • $4M in grant applications in process
  • Four pilots are planned to begin in the fall of this year














About BioLargo, Inc.
BioLargo, Inc. is an innovative technology incubator and environmental engineering company driven by a mission to “make life better” by delivering robust, sustainable solutions for a broad range of industries and applications, with a focus on clean water, clean air, and advanced wound care. We incubate disruptive technologies by providing the capital, support, and expertise to expedite them from “cradle” to “maturity” (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, Odor-No-More (www.odornomore.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System “AOS”, a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. Our subsidiary Clyra Medical (www.clyramedical.com) features effective and gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

Monday, 16 July 2018

BioLargo Spotlight: BioLargo Water Shortlisted for Clean Growth Program Funding to Target Oil Sands Process Affected Water (OSPW) Treatment


Today we are pleased to announce that our subsidiary BioLargo Water, Inc. has been shortlisted for the Clean Growth Program (CGP), Natural Resources Canada’s new flagship $155M funding program for innovative clean technologies. BioLargo Water’s application, if successful, will provide over $1.5M CAD over two years to validate the ability for our Advanced Oxidation System (AOS) to eliminate troublesome and environmentally harmful compounds from oil sands process affected water (OSPW). These compounds represent a challenge with serious impacts on land reclamation, remote and aboriginal communities, and the Canadian oil and gas industry. You can see Natural Resources Canada’s announcement HERE, including the list of semi-finalists.

 

BioLargo Water was one of 92 companies shortlisted for Clean Growth Program funding, and was chosen from a pool of over 750 submissions. The list of 92 semi-finalists includes industry and innovation heavyweights including Barrick Gold, CNRL, Imperial Oil, Suncor, and numerous leading universities in Canada. We are very proud of our BioLargo Water team for having been selected as a semi-finalist, and they are hard at work to produce a winning full proposal by the deadline in August.

Delivering a technology that can provide effective and cost-efficient treatment and remediation of OSPW in the oil sands industry has, from BioLargo’s inception, been one of the utmost priorities for the company. When we first began developing a water treatment technology it was due mainly to industry pull in the oil & gas sector, where we sponsored a University of Alberta Industrial Research Chair with some of the top oil companies in Canada to tackle this very purpose. Since that time, we have steadily progressed our work on the AOS for OSPW treatment. We have a high level of confidence in our ability to scale up the technology, and we have an incredible team of scientists and engineers capable of supporting this project and the work required to properly vet it for this demanding market. This project, with proposed funding from the CGP, has the potential to quickly accelerate our development work to bring our AOS to the oil and gas industry as an effective and cost-efficient solution for treating OSPW.

As always, we remind our followers that the award is not assured, but we are optimistic about our eventual commercial success in this targeted treatment area. This funding would be a major boost to accelerating our commercial plans!  #GoBioLargo


What is a BioLargo Spotlight?
It’s an exciting time at BioLargo. We’re moving fast, and it can be difficult to keep our stockholders and the investing public informed of our progress. In light of this, we will be posting a series of short articles titled “BioLargo Spotlight”, highlighting certain business activities and other important information in between our required SEC filings. Of course, these do not replace our public filings, which contain more complete information than can be delivered in this forum, and thus we urge you to carefully read and rely on those filings for definitive information, and to review our risk factors and caution regarding forward-looking statements. We are optimistic about our business as we work hard to continue to grow and ultimately generate profits for our stockholders.   

Legal Disclaimer
Our attorneys remind us that while we believe these developments are important and that these small victories could add up and lead to big victories, at this stage they do not rise to the level of an official material disclosure. As the size and magnitude of these developments become material, we will naturally report that information in an 8-K and our regular SEC filings.


widget